Hepatocellular carcinoma (HCC) is one of the most common malignancies and the fourth leading cause of cancer-related death worldwide. Our previous study showed that EYA4 functioned by suppressing growth of HCC tumor cells, but its molecular mechanism is still not elucidated. Based on the results of gene microassay, EYA4 was inversely correlated with MYCBP and was verified in human HCC tissues by immunohistochemistry and western blot. Overexpressed and KO EYA4 in human HCC cell lines confirmed the negative correlation between EYA4 and MYCBP by qRT-PCR and western blot. Transfected siRNA of MYCBP in EYA4 overexpressed cells and overexpressed MYCBP in EYA4 KO cells could efficiently rescue the proliferation and G2/M arrest effects of EYA4 on HCC cells. Mechanistically, armed with serine/ threonine-specific protein phosphatase activity, EYA4 reduced nuclear translocation of β-catenin by dephosphorylating β-catenin at Ser552, thereby suppressing the transcription of MYCBP which was induced by β-catenin/LEF1 binding to the promoter of MYCBP. Clinically, HCC patients with highly expressed EYA4 and poorly expressed MYCBP had significantly longer disease-free survival and overall survival than HCC patients with poorly expressed EYA4 and highly expressed MYCBP. In conclusion, EYA4 suppressed HCC tumor cell growth by repressing MYCBP by dephosphorylating β-catenin S552. EYA4 combined with MYCBP could be potential prognostic biomarkers in HCC. K E Y W O R D S beta-catenin, EYA4, hepatocellular carcinoma, MYCBP, tumor suppressing gene | 3111 ZHU et al.
| INTRODUC TI ON
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. 1 HCC is prevalent in China because of a high rate of hepatitis B virus (HBV) infection. Alcohol abuse and obesity are considered as contributory factors to the increasing incidence of HCC in western countries. 2 Even though surgery, local ablation therapy and transarterial chemoembolization (TACE) have effectively prolonged the life of HCC patients, recurrence of HCC is still an intractable problem that needs to be resolved urgently. 1, 3 Molecular-target therapy, such as sorafenib, has been widely used in advanced HCC, but it can prolong OS by <3 months only compared with placebo (10.7 months vs 7.9 months). 4 Therefore, better understanding of the molecular mechanisms of HCC carcinogenesis and progression would provide a new therapeutic target, and are of scientific and clinical significance. 5 Recent studies have shown that aberrant methylation of EYA4 is a potential biomarker in colorectal cancer, urothelial bladder cancer, esophageal squamous cell carcinoma and pancreatic cystic neoplasms. [6] [7] [8] [9] [10] In our previous studies, we demonstrated that EYA4 was highly methylated in HCC and related to the prognosis of HCC patients. 11 We also clarified that EYA4 functioned as a tumor suppressor gene in HCC. 12 However, the mechanisms of how EYA4 exerts its tumor suppression effect have not been well defined. In order to explore the mechanisms through which EYA4 suppresses HCC tumorigenesis and progression, a gene expression microarray analysis was done in our previous study. 12 The results showed that MYCBP was downregulated in EYA4 overexpressed cells compared with control. MYCBP is an protein that can associate with MYC and stimulate the activation of transcription. 13, 14 Increased expression of MYC can facilitate MYCBP translocation into the nucleus in the S phase of the cell cycle and influence proliferation, differentiation and apoptosis of cells. 13 Recently published papers showed that MYCBP played an important role in lung cancer, gastric cancer, glioma, esophageal squamous cancer and acute myeloid leukaemia. [14] [15] [16] [17] [18] However, it still remains unknown as to whether MYCBP plays a role in HCC.
In the present study, we aimed at elucidating the molecular mechanisms of how EYA4 interacts with MYCBP to repress HCC. Written informed consent was obtained from all patients.
| MATERIAL S AND ME THODS

| Human specimens
| Extraction and processing of Gene Expression Omnibus
One Affymetrix HT Human Genome U133A Array dataset (GSE14520) and one Affymetrix Human Genome U133 Plus 2.0 F I G U R E 1 EYA4 negatively correlates with MYCBP in human hepatocellular carcinoma (HCC) tissues. A and B, Gene expression microarray results of the related expression level of MYCBP in EYA4 overexpressed (EYA4+) (A) HCC cell lines and EYA4 knockdown (EYA4−) (B) HCC cell line compared with control. C, Western blot results of EYA4 and MYCBP expression in human HCC tissues. D, Paired dot plot shows that based on the results of (E), EYA4 was negatively correlated with MYCBP in human HCC tissues. E, Immunohistochemical staining shows the correlation of EYA4 and MYCBP in HCC patient tissues. F, Bar graphs indicate that in human HCC tissue, MYCBP expression was significantly different in EYA4 highly expressed tissues and EYA4 poorly expressed tissues. G and H, Dot plot shows different expression of MYCBP in HCC patient tissues (T) and non-cancerous human liver tissues (N) from datasets GSE14520 (G) and GSE45436 (H). (Scale bar = 50 μm; *P < .05, **P < .01, ***P < .001, ****P < .0001) Array (GSE45436) were selected. The raw data were downloaded from the Gene Expression Omnibus (GEO) database ( https ://www. ncbi.nlm.nih.gov/gds/). The array data of GSE14520 included 225 human HCC tissue samples and 220 non-cancerous human liver tissue samples. The dataset of GSE45436 consisted of 93 human HCC tissue samples and 41 non-cancerous human liver tissue samples.
The specific analysis method has been described previously. 19 
| Survival analysis on Gene Expression Profiling Interactive Analysis platform
The online database Gene Expression Profiling Interactive Analysis (GEPIA) ( http://gepia.cancer-pku.cn/index.html) was used to generate survival curves, including disease-free survival and overall survival. Survival analysis was carried out on a GEPIA platform based on gene expression. In the present study, liver hepatocellular carcinoma (LIHC) was selected.
| Histopathology and immunohistochemistry
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Immunohistochemistry (IHC) staining was carried out on 3-μm paraffin sections. The following antibodies were used: rabbit antihuman EYA4 (1:50, Abcam ab102648), rabbit anti-human MYCBP (1:50, Abcam ab66331). IHC score ( Figure 1E ) is the product of staining intensity × proportion of positive cells. Staining intensity (0, negative; 1, mild; 2, moderate; 3, severe) and proportion of positive cells (0, ≤10%; 1, >10% and ≤25%; 2, >25% and ≤50%; 3, >50% and ≤75%; 4: >75%) were quantified, respectively. Two experienced pathologists scored the stained tissues independently. Percentage of specimens in Figure 1F was based on the IHC score of Figure 1E . From Figure 1E , we obtained the median IHC score of EYA4 and MYCBP.
In Figure 1F , HCC patients were first separated into two groups (High EYA4 or Low EYA4) with the median IHC score of EYA4. In each group, HCC patients were separated into High MYCBP or Low MYCBP subgroups based on the median IHC score of MYCBP. Then we obtained the percentage of MYCBP (High/Low) in High EYA4 or Low EYA4 groups separately. 
| Cell culture
| Western blot
Western blot was carried out by standard method using the following antibodies: rabbit anti-human EYA4 (1:1000, Abcam ab102648), rabbit anti-human MYCBP (1:500, Abcam ab66331), rabbit antihuman β-catenin (1:1000, CST #8480), rabbit anti-human β-catenin (Ser675) (1:1000, CST #4176), rabbit anti-human β-catenin (Ser552) (1:1000, CST #5651). ImageJ was used to measure the integrated density ( Figure 1F ) of each blot from Figure 1C . The integrated density reflected the expression level of the blot. Maximum value of the expression level of the blot was set as 100%, and other blots obtained their relative expression levels.
| Immunofluorescence staining
Cells were seeded on glass coverslips and then fixed with 4% paraformaldehyde for 20 minutes and washed three times with PBS for 5 minutes each. Cells were permeabilized with 0.1% Triton X-100 (Solarbio #T8200) for 10 minutes and washed three times with PBS for 5 minutes each. They were then blocked in 10% goat serum (Thermo Fisher Scientific #16210072) for 1 hour at room temperature. Incubation with β-catenin antibody (1:200, Abcam ab32572) was carried out at 4°C for 16 hours. Nuclei were counterstained with DAPI (Thermo Fisher Scientific #P36931). Images of cultured cells were obtained through using the ZEISS Laser Scanning Confocal Microscope LSM710 with oil ×67 magnification lenses, and ZEN 2.3 software was used. Table 1 . All primers were obtained from Sangon Biotech.
| Quantitative real-time PCR
| Cell Counting Kit-8 for cell proliferation
Cell Counting Kit-8 (Dojindo CK04) was used for measuring cell proliferation. We dispensed 100 μL cell suspension (5000 cells/ well) in a 96-well plate. The plate was preincubated for 24 hours in a humidified incubator (37°C, 5% CO 2 ) and then incubated for a range of times (12, 24, 48, 72, 96 hours). CCK-8 solution (10 μL) was added to each well of the plate and the plate was incubated for 1 hour. Absorbance at 450 nm was measured using a microplate reader.
| Colony formation assay
Cells were seeded in 6-well plates at equal densities (200 and 500 cells). They were allowed to form colonies for 2-3 weeks. Medium was changed every week. After 2-3 weeks, we replaced the medium and washed the plates with PBS. Cells were fixed with 2 mL of 4% paraformaldehyde for 20 minutes. After replacing the stained the colonies with 1% crystal violet for 30 minutes, the plates were washed with PBS and allowed to dry. We took pictures of these plates and calculated colony numbers with ImageJ.
| Propidium iodide staining of DNA
Cells were harvested by 0.25% trypsin and washed in PBS. Cells were fixed in 70% ethanol added drop wise to the cell pellet while vortexing and fixed for 30 minutes at 4°C. Cells were washed in PBS twice. Cells were centrifuged at 2000 rpm which removed the ethanol. RNAse (5 μL of 1 mg/mL; Sigma 10109134001) was added. Then, 300 μL propidium iodide (50 μg/mL) was added and cells incubated in the dark for 30 minutes. We ran the flow cytometer, chose single cells and quantitated the percentage of cells in each cell cycle phase by FlowJo.
| Plasmid sgRNAs and siRNAs
β-Catenin S552 A mutation plasmid was constructed with QuickMutation Site-Directed Mutagenesis Kit obtained from Beyotime Biotechnology (D0206). The sequences are shown in Table 1 . CRISPR/Cas9 sgRNAs that targeted EYA4 were designed using http://crisp or.tefor.net/. The sequences are shown in 
| Luciferase reporter gene assay
| Statistical analysis
| RE SULTS
| EYA4 negatively correlates with MYCBP in human HCC tissues and cell lines
In our previous study, we carried out gene expression microassay in HCC overexpressed cell lines and HCC knockdown cell lines compared with control. The results showed that MYCBP was poorly expressed in EYA4 overexpressed cell lines and highly expressed in EYA4 knockdown cell lines ( Figure 1A,B ). These results indicated that EYA4 may be negatively correlated with MYCBP.
To verify the correlations between EYA4 and MYCBP in human HCC tissues, we tested the expression of EYA4 and MYCBP in 18 HCC patient tissues by western blot. The results showed that EYA4 was negatively correlated with MYCBP (r = −.524, P = .025) ( Figure 1C ,D).
In addition, 100 patients who were diagnosed with HCC and had had hepatectomy at The First Hospital of Sun Yet-sen University were randomly selected and protein expression of EYA4 and MYCBP by IHC was carried out. The results showed that 40 tissues expressed a high level of EYA4, whereas 60 tissues expressed a low level of EYA4. In tissues with highly expressed EYA4, 26 (65%) tissues had low MYCBP protein expression. In tissues with poorly expressed EYA4, 32 (53%) tissues had high MYCBP protein expression (P = .0042) ( Figure 1E ( Figure 1G,H) . This indicated that MYCBP might play an important role in promoting HCC progression. Therefore, we hypothesized that EYA4 functions as a tumor suppressor gene by inhibiting MYCBP expression.
We then verified the gene expression microarray results in human HCC cell lines. We generated EYA4 overexpressed cell lines and EYA4 KO cell lines in Huh7 and PLC/PRF/5, respectively.
According to the microarray results, MYCBP was significantly poorly expressed in EYA4 overexpressed cell lines. MYCBP in EYA4 KO cell lines was significantly highly expressed ( Figure 2 ). In Figure 2C , Huh-7 CR-1 and Huh-7 CR-2 both expressed a higher level of MYCBP compared with control. However, Huh-7 CR-1 had a higher level of MYCBP compared with Huh-7 CR-2. We thought this was because of the heterogeneity of tumor cells. Different tumor cells responded a little differently when knocked out EYA4. As MYCBP was upregulated in both CR-1 and CR-2, we considered that it was reasonable to conclude that knocked out EYA4 could increase the expression level of MYCBP.
| EYA4 suppressed HCC tumor cell growth by inhibiting MYCBP expression
To explore whether MYCBP is the key to mediating the tumor sup- Figure 3J ). Cell proliferation, as measured by colony assay and survival curves, were attenuated when EYA4 was overexpressed, but this effect was rescued by transfecting MYCBP (Figure 3B-G) . Cell cycle analysis, which also reflects cell proliferation, showed that the G2/M phase was arrested when EYA4 was overexpressed, but this effect was rescued by transfecting MYCBP (Figure 3H,I) . Additionally, EYA4 KO cells showed enhanced proliferation ability in colony assay, survival curves and cell cycle analysis. This enhancement was also inhibited by transfecting siRNA of MYCBP ( Figure 3K-R) . Therefore, these results showed that EYA4 suppressed HCC tumor cell growth by inhibiting MYCBP expression.
| EYA4 mediates MYCBP by dephosphorylating β-catenin at S552
We subsequently aimed to illuminate the mechanism of how EYA4 mediates MYCBP in HCC cells. MYCBP was reported as a direct target of the β-catenin/LEF-1 pathway through its LEF-1 binding sites in the MYCBP promoter. EYA4 is known as a phosphatase.
In our previous studies, EYA4 could dephosphorylate β-catenin at S675 in pancreatic cancers. β-Catenin, the stabilization of which can be modified by phosphorylation/dephosphorylation at S33/ S37, T41/S45, S552 and S675, is a key point in Wnt signal pathways.
Therefore, we hypothesized that EYA4 may mediate MYCBP by dephosphorylating β-catenin. To verify this hypothesis, we carried out western blot in EYA4 overexpressed cells and EYA4 KO cells.
The results showed that phospho β-catenin S552 was decreased in EYA4 overexpressed cells and increased in EYA4 KO cells, but the total β-catenin did not change, nor did phospho β-catenin S675 ( Figure 4A ). This result indicated that EYA4 can dephosphorylate β-catenin at S552. To investigate whether the phosphorylation/ dephosphorylation switch of β-catenin S552 can influence the expression level of MYCBP, we cloned plasmids of β-catenin without (WT) or with S552A mutation and transfected the plasmids to EYA4 overexpressed cells, respectively. When transfected with the same amount of total β-catenin, the MYCBP protein level was significantly higher in cells transfected with WT β-catenin than in cells transfected with S552A mutation β-catenin ( Figure 4B ). Consist with our hypothesis, these results confirmed that EYA4 mediates MYCBP by dephosphorylating β-catenin at S552. 
| EYA4 reduced the nuclear translocation of β-catenin followed by suppression of transcription of MYCBP
| EYA4 combined with MYCBP as potential prognostic biomarkers in HCC
In our previous studies, we showed that EYA4 was an independent prognostic biomarker in HCC. EYA4 expression was positively related to disease-free survival (DFS) and overall survival (OS) of HCC patients. In the present study, we reconfirmed the prognostic value of EYA4. EYA4 was an independent prognostic biomarker for DFS and OS of HCC patients ( Table 2 ). HCC patients with highly expressed EYA4 had longer survival time compared with poorly expressed EYA4 patients, with a median DFS of 31 months vs 19 months (P = .019) ( Figure 5A ) and a median OS of 51 months vs 42 months (P = .033) ( Figure 5D ). Meanwhile, in the present study, it was proven that MYCBP is an independent prognostic biomarker for DFS and OS of HCC patients ( vs 32 months (P = .002) ( Figure 5B ) and a median OS of 38 months vs 54 months (P = .002) ( Figure 5E ). In addition, from the GEPIA platform, we also found that HCC patients with highly expressed MYCBP had shorter DSF and OS compared with HCC patients with poorly expressed MYCBP (P < .05) ( Figure 5G,H Figure 5C,F) . These results indicated that EYA4 combined with MYCBP could be potential prognostic biomarkers in HCC.
| D ISCUSS I ON
In our previously published studies, we explained that EYA4 was poorly expressed in HCC tumor tissue compared with pericarcinomatous tissue. We also showed that EYA4 is a tumor suppressor gene in HCC. To explore the mechanism of how EYA4 functions, we carried out a comparative study of the transcriptome profiles of human HCC cell lines (Huh7 and PLC/PRF/5) overexpressing EYA4 with that of control by gene expression microarray analysis. Results showed that MYCBP was significantly poorly expressed in EYA4 overexpressed cell lines compared with control.
In order to verify the correlation between EYA4 and MYCBP, MYCBP was reported as a direct target of the β-catenin/LEF-1 pathway. 15, 22 EYA4 was shown to mediate the Wnt pathway by dephosphorylating β-catenin Ser675 in pancreatic cancer. 15, 23 Therefore, we hypothesized that EYA4 may mediate MYCBP by dephosphorylating β-catenin. β-Catenin is one of the core proteins in the Wnt signaling pathway, and it was shown that phosphorylation at Ser552 and Ser675 of β-catenin could activate the β-catenin mediated signaling pathway. [24] [25] [26] In this study, in EYA4 overexpressed cells and EYA4 KO cells, the total level of β-catenin and p675-β-catenin did not change, but the level of p552-β-catenin was decreased in EYA4 overexpressed cells and increased in EYA4 KO cells. To investigate whether p552-β-catenin can facilitate transcription of MYCBP, we established β-catenin overexpressed plasmids with (WT) or without S552A mutation, a negative phosphorylated mutation of β-catenin at Ser552. 27 Then we transfected WT and S552A plasmids in EYA4 overexpressed cells. Results showed that the transcription level of MYCBP was higher in cells transfected with control plasmids than in S552A mutated plasmids. These results indicated that EYA4 downregulates MYCBP by dephosphorylating β-catenin at Ser552. In summary, we demonstrated that EYA4 reduced the nuclear translocation of β-catenin by dephosphorylating β-catenin at Ser552, therefore suppressing the transcription of MYCBP which was induced by β-catenin/LEF1 binding to the promoter of MYCBP.
Our previous study showed that EYA4 was an independent prognostic factor in HCC. Higher expression of EYA4 was associated with a better DFS and OS. 12 In the present study, we reconfirmed the prognostic effect of EYA4 and also showed that MYCBP was an in- 
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